Bart Geers

Tavira Therapeutics is a spin-off from KU Leuven developing a modular next-generation AAV capsid platform, with the goal of enhancing tissue-specific transgene delivery for gene therapy

AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first in class Plug & Play vaccine platform with a patented DNA based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.

Augustine Therapeutics is a biotechnology company focused on the treatment of neuromuscular, neurodegenerative and cardio-metabolic diseases through its next-generation approach to selectively inhibit HDAC6. Augustine’s HDAC6 inhibitors have been purposefully designed to selectively inhibit HDAC6 while preserving its beneficial non-catalytic functions. Augustine’s lead program, AGT-100216, is the first selective HDAC6 inhibitor for long-term treatment of Charcot-Marie-Tooth (CMT) disease. With its novel non-hydroxamate, non-hydrazide producing chemotype, Augustine’s HDAC6 approach is selective, avoids the limitations of other chemotypes, and built for chronic diseases. With this novel approach, the Company will also be targeting diseases beyond CMT, including neurodegenerative and cardio-metabolic diseases. Augustine Therapeutics was founded on the ground-breaking research of Prof. Ludo Van Den Bosch from the VIB-KU Leuven in Belgium. ——— *Disclaimer* ——— We wish to caution jobseekers that Augustine Therapeutics, only recruits for the positions that are posted on the company’s webpage and via the channels mentioned there. It will also not charge fees of any kind from candidates during the recruitment process. Any person or organization dealing with unauthorized parties is doing so at their own risk.

We are a medical device company developing the ultimate ultrasound patch to monitor cardiac performance continuously, safely and non-invasively.

FOx Biosystems aims to revolutionize the life sciences industry and research market using its real-time, label-free analysis technology. The FOx technology is based on an innovative fiber-optic-based surface plasmon resonance biosensor technology. This enables the users to generate high quality biomolecular data such as affinity data, kinetic data and concentration measurements. FOx biosensor technology has several benefits compared to existing biomolecular analysis tools, including ease of use, speed, wide applicability and cost-effectiveness. FOx Biosystems sells instruments, reagents and services to improve biomolecular interaction analysis in life science research and industry. FOx Biosystems was founded in 2016 as a spin-off of the KU Leuven and still closely collaborates with the university for further innovations.

Tavira Therapeutics is a spin-off from KU Leuven developing a modular next-generation AAV capsid platform, with the goal of enhancing tissue-specific transgene delivery for gene therapy

AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first in class Plug & Play vaccine platform with a patented DNA based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.

Augustine Therapeutics is a biotechnology company focused on the treatment of neuromuscular, neurodegenerative and cardio-metabolic diseases through its next-generation approach to selectively inhibit HDAC6. Augustine’s HDAC6 inhibitors have been purposefully designed to selectively inhibit HDAC6 while preserving its beneficial non-catalytic functions. Augustine’s lead program, AGT-100216, is the first selective HDAC6 inhibitor for long-term treatment of Charcot-Marie-Tooth (CMT) disease. With its novel non-hydroxamate, non-hydrazide producing chemotype, Augustine’s HDAC6 approach is selective, avoids the limitations of other chemotypes, and built for chronic diseases. With this novel approach, the Company will also be targeting diseases beyond CMT, including neurodegenerative and cardio-metabolic diseases. Augustine Therapeutics was founded on the ground-breaking research of Prof. Ludo Van Den Bosch from the VIB-KU Leuven in Belgium. ——— *Disclaimer* ——— We wish to caution jobseekers that Augustine Therapeutics, only recruits for the positions that are posted on the company’s webpage and via the channels mentioned there. It will also not charge fees of any kind from candidates during the recruitment process. Any person or organization dealing with unauthorized parties is doing so at their own risk.

We are a medical device company developing the ultimate ultrasound patch to monitor cardiac performance continuously, safely and non-invasively.

FOx Biosystems aims to revolutionize the life sciences industry and research market using its real-time, label-free analysis technology. The FOx technology is based on an innovative fiber-optic-based surface plasmon resonance biosensor technology. This enables the users to generate high quality biomolecular data such as affinity data, kinetic data and concentration measurements. FOx biosensor technology has several benefits compared to existing biomolecular analysis tools, including ease of use, speed, wide applicability and cost-effectiveness. FOx Biosystems sells instruments, reagents and services to improve biomolecular interaction analysis in life science research and industry. FOx Biosystems was founded in 2016 as a spin-off of the KU Leuven and still closely collaborates with the university for further innovations.